Giulia Pesch
YOU?
Author Swipe
View article: Supplementary Figure 8 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 8 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 8: Immunohistochemistry of mucosal tissues from irColitis and ulcerative colitis patients
View article: Data from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Data from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Although initially assumed to be similar, immune checkpoint inhibitor (ICI)–induced autoimmunity can differ from spontaneous autoimmune disease in regard to clinical presentation, pathogenesis, and therapy. Despite limited pathogenetic und…
View article: Supplementary Table 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Table 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
List of all differentially expressed genes and enriched pathways for gene expression analyses
View article: Supplementary Table 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Table 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Table 1: Patient characteristics
View article: Supplementary Table 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Table 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Table 3: List of FACS antibodies with respective antigens, fluorophores and clones
View article: Supplementary Figure 6 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 6 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 6: Activation and exhaustion marker co-expression on T cell subsets of irColitis and ulcerative colitis patients
View article: Supplementary Figure 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 2: Transcriptional analysis of irColitis and ulcerative colitis dependent on severity
View article: Supplementary Figure 5 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 5 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 5: Activation and exhaustion marker expression on T cell subsets of irColitis and ulcerative colitis patients
View article: Supplementary Figure 7 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 7 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 7: DC subset distribution in irColitis and ulcerative colitis patients
View article: Supplementary Figure 4 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 4 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 4: Representative gating strategies of FACS panels
View article: Supplementary Figure 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 3: Transcriptional analysis of healthy PBMC compared to irColitis PBMC
View article: Supplementary Figure 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 1: Transcriptional analysis of healthy colon mucosa compared to mucosa of irColitis and ulcerative colitis patients
View article: Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity Open
Background Immune checkpoint inhibitor (ICI)-induced myocarditis is a rare immune-related adverse event (irAE) with a fatality rate of 40%–46%. However, irMyocarditis can be asymptomatic. Thus, improved monitoring, detection and therapy ar…
View article: Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma Open
Predictive markers for immune checkpoint inhibitor (ICI) therapy are needed. Thus, baseline blood counts have been investigated as biomarkers, showing that lymphopenia at the start of therapy with (ICI) is associated with a worse outcome i…